Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947731 | 0.84 | ALDH1A1 (0.56) | F10ALDH1A1KDM4EPPARGHTT | |
| SCHEMBL14029051 | 0.83 | GAA (0.63) | MMP2MMP7MMP14GAAALDH1A1 | |
| SCHEMBL3671530 | 0.82 | NPC1 (0.69) | MMP2MMP7MMP14NPC1ALDH1A1 | |
| SCHEMBL7012000 | 0.81 | ALDH1A1 (0.72) | NPC1F10GAAALDH1A1KDM4E | |
| SCHEMBL7010156 | 0.81 | PPARG (0.52) | F10ALDH1A1PPARGHTT | |
| SCHEMBL7012908 | 0.81 | GAA (0.55) | NPC1F10GAAALDH1A1KDM4E | |
| SCHEMBL6554026 | 0.80 | NPC1 (0.67) | MMP2MMP7MMP14NPC1ALDH1A1 | |
| SCHEMBL6554003 | 0.80 | NPC1 (0.67) | MMP2MMP7MMP14NPC1ALDH1A1 | |
| SCHEMBL7013159 | 0.80 | PPARG (0.51) | F10ALDH1A1PPARGHTT | |
| SCHEMBL18503864 | 0.80 | ALDH1A1 (0.58) | MMP2MMP7MMP14GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | MMP2 4420/4885MMP7 3988/4885MMP14 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.